No Prescription |
 |
 | ||
|
EFEXOR Effexor XR |
|
| ||
No Prescription » Prescription Drugs 6 » EFEXOR Effexor XR Treating depression. Venlafaxine is an antidepressant in a group of drugs called selective serotonin and norepinephrine reuptake inhibitors (SSNRIs). Venlafaxine affects chemicals in the brain that may become unbalanced and cause depression.Venlafaxine is used to treat major depressive disorder anxiety and panic disorder.Effexor is prescribed for the treatment of depression--that is a continuing depression that interferes with daily functioning. The symptoms usually include changes in appetite sleep habits and mind/body coordination decreased sex drive increased fatigue feelings of guilt or worthlessness difficulty concentrating slowed thinking and suicidal thoughts.Effexor is a serotonin and norepinephrine reuptake inhibitor (SNRI). It works by restoring the balance of certain natural substances in the brain (serotonin and norepinephrine) which helps to improve certain mood problems. Buy EFEXOR Effexor XR and other Prescription Drugs 6 products online at Medstore. 3564
About EFEXOR Effexor XR: Product Type: Prescription Drugs 6 EFEXOR ( Effexor XR Generic Venlafaxine ) EFEXOR (Effexor XR Generic Venlafaxine) Effexor XR Generic Venlafaxine 37.5mg 28 capsules Effexor XR Generic Venlafaxine EFEXOR
View more Prescription Drugs 6 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
